Skip to main content

Table 1 Studies according to the study population baseline characteristics.

From: Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

Characteristics of study populations
Study Number a Mean age Line of treatment Type of lymphoma HIV status HBV status
  Intervention control      
Aviles 2007a 102 102 69.2 untreated aggressive neg. anti-HBc -
Aviles 2007b 98 98 59.7 refractory aggressive neg. anti-HBc -
Aviles 2010 47 53 50.0 refractory aggressive neg. anti-HBc -
Buske 2009 36 33 60.5 untreated indolent neg.* NR
Coiffier 2002 202 197 69.0 untreated aggressive# neg. HBsAg -
Eve 2009 78 78 63.5 untreated indolent neg. anti-HBc -
Forstpointner 2004 66 62 62.5 refractory indolent neg.* NR
Habermann 2006 267 279 69.5 untreated aggressive neg. NR
Herold 2007 105 96 58.5 untreated indolent neg. NR
Hiddemann 2005 223 205 55.5 untreated indolent neg.* NR
Kaplan 2005 99 51 42.7 untreated aggressive pos. NR
Lenz 2005 62 60 61.5 untreated indolent neg.* NR
Marcus 2005 162 159 52.5 untreated Indolent § neg. HBsAg -
Pfreundschuh 2008a 304 305 68.5 untreated aggressive# neg. NR
Pfreundschuh 2008b 306 307 68.0 untreated aggressive# neg. NR
Robak 2010 276 276 62.5 refractory indolent neg. HBsAg-
van Oers 2006 234 231 54.5 refractory indolent neg. NR
  1. a) number of patients included either in the control and intervention arm; NR = not reported; § this includes 1.2% undefined lymphomas; # this includes 6 to 20% proportion of indolent or undefined; * HIV status not specified and presumed as negative.